Cerity Partners
UBX

Cerity Partners’s Unity Biotechnology UBX Stock Holding History

Cerity Partners’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,000
Closed -$348K – 488
2020
Q1 		$348K Buy
6,000
+500
+9% +$31.5K 0.02% 323
2019
Q4 		$397K Buy
5,500
+2,280
+71% +$161K 0.02% 375
2019
Q3 		$196K Buy
3,220
+20
+0.6% +$1.42K 0.01% 457
2019
Q2 		$304K Hold
3,200
– – 0.02% 399
2019
Q1 		$260K Buy
3,200
+1,280
+67% +$145K 0.02% 447
2018
Q4 		$312K Buy
+1,920
New +$255K 0.02% 395

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cerity Partners's UBX Position: Q2 2020 in Review

Cerity Partners sold out of Unity Biotechnology (UBX) in Q2 2020, closing a stake of 6,000 shares — an estimated $348K sold.

Cerity Partners first reported a position in UBX in Q4 2018 and held it in 6 quarters. The position peaked at $397K in Q4 2019. 84 funds tracked by Wall St. Rank hold UBX as of Q2 2020.

  • Cerity Partners reported no remaining Unity Biotechnology position as of Q2 2020 after selling out during the quarter.
  • Cerity Partners sold 6,000 Unity Biotechnology shares in Q2 2020, an estimated $348K.
  • Cerity Partners first reported a position in Unity Biotechnology in Q4 2018 and held it in 6 quarters.
  • Cerity Partners's Unity Biotechnology position peaked at $397K in Q4 2019.
  • 84 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2020.

Based on Cerity Partners's 13F filing for Q2 2020, filed 14 Aug 2020.